[{"orgOrder":0,"company":"Forbion","sponsor":"Inversago Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Forbion","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Gyroscope Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2021","type":"Series C Financing","leadProduct":"GT005","moa":"Complement Factor I production","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Forbion","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"F2G Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Forbion","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Azafaros","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Forbion","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"1","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"VRB-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Forbion","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Oxular","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Financing","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Forbion","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Injection, Sustained Release","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Anaveon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"ANV419","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forbion","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Kynexis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Forbion","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"SynOx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"Emactuzumab","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Forbion","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Noema Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Forbion","amount2":0.11,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"9","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Calluna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Forbion","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"ARMGO Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"ARM210","moa":"RYR1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Forbion","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PJS-539","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Forbion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forbion \/ Undisclosed"},{"orgOrder":0,"company":"Forbion","sponsor":"enGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2023","type":"Financing","leadProduct":"Detalimogene Voraplasmid","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Forbion","amount2":0.12,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Liquid, Instillation","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"7","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Granite Bio","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"GRT-001","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Forbion","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"LoQus23 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Forbion","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"VectorY","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Forbion","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"Forbion \/ Forbion"},{"orgOrder":0,"company":"Forbion","sponsor":"Progentos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Forbion","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Forbion \/ Forbion","highestDevelopmentStatusID":"5","companyTruncated":"Forbion \/ Forbion"}]

Find Clinical Drug Pipeline Developments & Deals by Forbion

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The financing aims to fund the development of Granite pipeline including GRT-001, it depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. It is being evaluated for IBD.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          April 24, 2025

                          Lead Product(s) : GRT-001

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I

                          Recipient : Granite Bio

                          Deal Size : $100.0 million

                          Deal Type : Series B Financing

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The financing aims to advance the clinical development of the company pipeline product, which includes VRB-101 an oral, once-weekly GLP-1 receptor agonist for obesity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : VRB-101

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Recipient : Verdiva Bio

                          Deal Size : $411.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The proceeds from the financing will be primarily used to support the pre-clinical development and initial clinical studies of LoQus23's lead program, an allosteric small molecule MutSβ inhibitor.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 02, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Recipient : LoQus23 Therapeutics

                          Deal Size : $43.0 million

                          Deal Type : Series A Financing

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The financing aims to fund the Progentos, which is developing first-in-class small molecules designed to induce remyelination of axons affected by multiple sclerosis.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 20, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Recipient : Progentos Therapeutics

                          Deal Size : $65.0 million

                          Deal Type : Series A Financing

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The proceeds will be used to advance late-stage product Emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          April 22, 2024

                          Lead Product(s) : Emactuzumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : SynOx Therapeutics

                          Deal Size : $75.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Calluna Pharma focuses on the clinical stage lead program CAL101, which is a monoclonal antibody that neutralizes the bioactivity of S100A4 & implements DAMP protein for idiopathic pulmonary fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 22, 2024

                          Lead Product(s) : Idelalisib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Recipient : Calluna Pharma

                          Deal Size : $81.1 million

                          Deal Type : Series A Financing

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 07, 2023

                          Lead Product(s) : KYN-5356

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Recipient : Kynexis Therapeutics

                          Deal Size : $62.1 million

                          Deal Type : Series A Financing

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The net proceeds are expected to be used to fund the clinical development of intravesical EG-70 (detalimogene voraplasmid), a monotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          May 17, 2023

                          Lead Product(s) : Detalimogene Voraplasmid

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : enGene

                          Deal Size : $115.0 million

                          Deal Type : Financing

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound NOE-101 (basimglurant), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in TN and sei...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 07, 2023

                          Lead Product(s) : Basimglurant

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Noema Pharma

                          Deal Size : $112.0 million

                          Deal Type : Series B Financing

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The proceeds from the financing with Shionogi & Co., Ltd., will enable F2G to advance late-stage development and commercialization in the US of F901318 (olorofim), a novel oral antifungal therapy to treat invasive aspergillosis and other rare mold infect...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          August 04, 2022

                          Lead Product(s) : Olorofim

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : F2G Limited

                          Deal Size : $70.0 million

                          Deal Type : Financing

                          blank